St Jude begins US trial for HF (heart failure) stimulation device:
This article was originally published in Clinica
St Jude Medical has begun the US portion of its clinical trial to assess its Genesis biventricular resynchronisation device as a treatment for heart failure (HF). The VecToR (Ventricular Resynchronization Therapy Randomized) trial will evaluate low-voltage biventricular stimulation versus no stimulation therapy and will collect and assess data on more than 420 HF patients from around 40 centres worldwide, said the St Paul, Minnesota company. The Genesis system consists of three components - the Frontier 3x2 stimulation device, the Aescula LV left-heart lead and a catheter delivery system.